Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer

• Junqun Liao ^[1] ; Yuan Ye ^[2] ; Xuren Xu ^[3]
  1. [1] First Affiliated Hospital of Chongqing Medical University

     First Affiliated Hospital of Chongqing Medical University

     China

     
  2. [2] Clinical Laboratory, Chongqing Nanchuan Maternity and Child Healthcare Hospital, Chongqing, 408400, China
  3. [3] Clinical Laboratory, The People’s Hospital of Nanchuan, Chongqing, No.16, Nandajie Road, Nanchuan District, Chongqing, 408400, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 10 (October), 2022, págs. 1986-1997
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Prostate adenocarcinoma (PRAD) is a high incidence of malignant tumor of the urinary system and the second most common male cancer in the world. Immune checkpoint inhibitor (ICIS) therapy is becoming a new hope for cancer treatment.

    Methods To realize the possibility of PRAD patients benefiting from ICIS treatment, we analyzed the mutation spectrum of all PRAD patients, calculated the TMB of each PRAD patient, and divided the patients into high TMB group and low TMB group. Differentially expressed genes (DEGs) between the two groups were identified and path analysis was carried out. The immune cell infiltration of each PRAD patient was evaluated and survival analysis was performed to explore the effect of immune cell infiltration on the prognosis.

    Results We found that high TMB was associated with better survival outcomes, with higher TMB scores in young patients, T2 and N0 patients. 28 hub genes were screened by the overlap between 229 DEGs and immune-related genes. T cells CD8 and CD4 memory activated in the high TMB group were higher than those in the low TMB group, while Mast cells resting in the low TMB group were higher than that in the high TMB group. High neutrophil infiltration is associated with poor prognosis in patients with PRAD. Finally, from the immune genes used to construct the prognostic risk model of TMB, it is found that CHP2 and NRG1 are independent prognostic factors of PRAD.

    Conclusions This study provides new insights into the immune microenvironment and potential immunotherapy of PRAD.